Compare DexCom, Inc. (DXCM) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Oxford Lane Capital Corp — how do they compare? DexCom, Inc. trades at $90.24 (market cap $33.79B), while Oxford Lane Capital Corp trades at $9.51 (market cap $909.61M). The key difference: DexCom, Inc. is far larger — about 37.1× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 25.76% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | OXLC | |
|---|---|---|
Market Cap | $33.79B | $909.61M |
Sector | Health | Financials |
52-Week High | $89.53 | $18.75 |
52-Week Low | $54.84 | $8.15 |
Enterprise Value | $33.24B | — |
Dividend Yield | — | 25.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
OXLC trades at $9.43, up 1.73% today, with a bullish technical signal from moving averages but mixed oscillators. The stock shows a low P/B of 0.88 but high P/S of 92.8, with recent earnings misses and a volatile net income margin of 100.85% in 2026. Dividends of $0.20 monthly are ongoing, while news highlights NAV discounts and sustainability concerns.
Outlook is cautious due to earnings volatility and high yield risks; opportunities include deep NAV discounts, but risks involve unsustainable distributions and negative ROE/ROA. Analyst consensus is split, with 50% buy ratings reflecting divided sentiment on recovery potential versus financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
